The TROPHAMET phase 1/2 nonrandomized clinical trial evaluated avelumab, a PD-L1 inhibitor, combined with methotrexate as first-line therapy for low-risk gestational trophoblastic tumors (GTT).
Among 26 assessable patients, serum hCG normalized in 96.2%, with no relapses observed after a median follow-up of 41 months.
The regimen was generally well tolerated; one dose-limiting toxicity occurred, and no grade 4 or higher adverse events were reported.
